Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results
Rhea-AI Summary
Legend Biotech (NASDAQ: LEGN) will host an investor conference call at 8:00 am ET on Tuesday, March 10, 2026 to review fourth-quarter and full-year 2025 results. The call includes a live audio webcast and a replay plus the earnings release available in Investor Relations approximately two hours after the call.
Investors can access the live webcast via the company link; management will provide an overview of quarterly and full-year financial performance.
Positive
- None.
Negative
- None.
News Market Reaction – LEGN
On the day this news was published, LEGN declined 1.27%, reflecting a mild negative market reaction. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $45M from the company's valuation, bringing the market cap to $3.49B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
LEGN is up 9% while peers show mixed moves: ABVX up 3.6%, CYTK up 0.6%, but AXSM, MRUS, and RYTM are down, indicating a stock-specific reaction rather than a broad biotech move.
Previous Conferences,earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 29 | Earnings call notice | Neutral | -1.4% | Announced date and access details for Q3 2025 results call. |
| Jul 28 | Earnings call notice | Neutral | -4.3% | Scheduled Q2 2025 earnings conference call and webcast logistics. |
| Apr 29 | Earnings call notice | Neutral | -0.8% | Outlined timing and replay plan for Q1 2025 results call. |
| Feb 25 | Earnings call notice | Neutral | +0.1% | Set schedule for Q4 and full-year 2024 earnings discussion. |
| Oct 24 | Earnings call notice | Neutral | +0.3% | Announced Q3 2024 earnings call timing and webcast access. |
Similar conference-call scheduling headlines have historically led to small, mixed share moves, often slightly negative.
Over the past year, Legend Biotech has repeatedly issued announcements scheduling investor conference calls for quarterly and full-year results. These "conferences,earnings" notices, such as those on Oct 24, 2024, Feb 25, 2025, and Oct 29, 2025, typically outlined timing, access details, and post-call replay availability. Price reactions around these events clustered near flat to mildly negative single‑day moves, suggesting the market generally treated them as routine informational updates rather than major catalysts.
Historical Comparison
Past "conferences,earnings" notices for LEGN saw an average move of -1.21%, making today’s 9% gain an unusually strong reaction versus prior scheduling updates.
The company has maintained a consistent pattern of pre-announcing quarterly and annual earnings calls, reinforcing regular disclosure practices around financial reporting.
Market Pulse Summary
This announcement schedules Legend Biotech’s investor call to review Q4 and full-year 2025 results, continuing its pattern of pre‑announcing quarterly earnings discussions with replay access a few hours later. In recent quarters, similar notices produced only modest share moves, while the stock has traded below its 200‑day MA of $30.33 and well under the $45.30 52‑week high. Investors may focus on how reported CARVYKTI sales, margins, and cash trends align with the profitability milestones highlighted in recent filings.
AI-generated analysis. Not financial advice.
SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 10, 2026, to review fourth-quarter and full-year 2025 financial results.
During the conference call and accompanying webcast, senior management will provide an overview of quarterly and full-year financial performance.
Investors and other interested parties may access the live audio webcast via this weblink.
A replay of the webcast, along with the earnings press release, will be available in the Investor Relations section of the Legend Biotech website under Events and Presentation approximately two hours after the conclusion of the call.
ABOUT LEGEND BIOTECH
With over 2,900 employees, Legend Biotech is the largest standalone cell therapy company and a pioneer in treatments that change cancer care forever. The company is at the forefront of the CAR-T cell therapy revolution with CARVYKTI®, a one-time treatment for relapsed or refractory multiple myeloma, which it develops and markets with collaborator Johnson & Johnson. Centered in the US, Legend is building an end-to-end cell therapy company by expanding its leadership to maximize CARVYKTI’s patient access and therapeutic potential. From this platform, the company plans to drive future innovation across its pipeline of cutting-edge cell therapy modalities.
Learn more at www.legendbiotech.com and follow us on X (formerly Twitter) and LinkedIn.
INVESTOR CONTACT:
Jessie Yeung
Tel: (732) 956-8271
jessie.yeung@legendbiotech.com
PRESS CONTACT:
Kim Fox
Tel: (848) 388-8445
media@legendbiotech.com
FAQ
When is Legend Biotech's (LEGN) conference call for Q4 and full-year 2025 results?
How can investors access the Legend Biotech (LEGN) live webcast for the March 10, 2026 call?
When will the replay and earnings press release for Legend Biotech (LEGN) be available after the March 10, 2026 call?
What will Legend Biotech (LEGN) management cover during the March 10, 2026 investor call?
